Cagrilintide 5mg
Cagrilintide 5mg
Cagrilintide is a long-acting acylated analogue of the pancreatic hormone amylin, designed for once-weekly subcutaneous administration. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake
|
Vial Size
|
Dose Range
|
Schedule
|
Primary Goal
|
|---|---|---|---|
| 5mg vial | 0.6 to 4.5 mg weekly with gradual titration every 2 weeks. | Weekly subcutaneous injections for 12 to 16 weeks (or longer as appropriate). | Support satiety, reduce food intake, and promote weight management over time. |
Reconstitution Summary
1 mL per 5 mg vial (5 mg/mL).
Storage Summary
Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw cycles.
Recommended Product
Cagrilintide 5mg
Reconstitution Steps
- Draw 1 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or vigorous agitation.
- Gently swirl or roll until fully dissolved (do not shake).
- Label with date and concentration; refrigerate at 2 to 8 °C, protected from light.
- Use within 30 days of reconstitution; discard if cloudy or particulate matter appears. At 5 mg/mL, 1 unit = 0.01 mL » 50 mcg on a U-100 insulin syringe.
How It Works
Cagrilintide is an acylated, long-acting analogue of amylin, a hormone co-secreted with insulin from pancreatic beta cells. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake. Lipid modifications extend its half-life to approximately 160 to 195 hours, enabling once-weekly dosing.
Benefits & Side Effects
- Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo.
- Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE
trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone. - Dose-dependent efficacy: Higher doses (2.4 to 4.5 mg) demonstrate greater weight loss than lower
doses (0.3 to 1.2 mg). - Side effects: Primarily gastrointestinal (nausea, vomiting, diarrhea, constipation), generally mild to
moderate and transient. Gradual titration helps minimize these effects. - Injection-site reactions: occasional mild redness or irritation at subcutaneous injection site
References & Scientific Literature
- Lau et al. Once-weekly cagrilintide for weight management: phase 2 dose-finding trial (The Lancet, 2021).
- Cagrilintide phase 2 trial: 10.8% weight loss at 4.5 mg dose over 26 weeks (The Lancet, 2021).
- REDEFINE 1: Coadministered cagrilintide and semaglutide in adults with overweight or obesity (NEJM, 2025).
- Development of cagrilintide: a long-acting amylin analogue (J Med Chem, 2021).